These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15269131)

  • 21. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
    Park K; Goto K
    Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
    Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
    Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
    Jiang H
    Jpn J Clin Oncol; 2009 Mar; 39(3):137-50. PubMed ID: 19088154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
    Padda SK; Chhatwani L; Zhou L; Jacobs CD; Lopez-Anaya A; Wakelee HA
    Anticancer Drugs; 2013 Aug; 24(7):731-5. PubMed ID: 23552470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
    Shao YY; Lin CC; Yang CH
    Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
    Stahel R; Rossi A; Petruzelka L; Kosimidis P; de Braud F; Bernardo MM; Souquet PJ; Parra HS; Gridelli C
    Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S19-23. PubMed ID: 14661049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib in advanced non-small cell lung cancer.
    Sharma R; Boyer M; Clarke S; Millward M
    Intern Med J; 2005 Feb; 35(2):77-82. PubMed ID: 15705135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
    Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
    Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib.
    Culy CR; Faulds D
    Drugs; 2002; 62(15):2237-48; discussion 2249-50. PubMed ID: 12381224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
    Forsythe B; Faulkner K
    Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.
    Gelibter A; Ceribelli A; Milella M; Mottolese M; Vocaturo A; Cognetti F
    J Exp Clin Cancer Res; 2003 Sep; 22(3):481-5. PubMed ID: 14582710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
    Natale RB
    Semin Oncol; 2004 Jun; 31(3 Suppl 9):23-30. PubMed ID: 15206079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.